title: Rotavirus infection and the current status of rotavirus vaccines.
abstract: Among children, rotaviruses are the most common cause of severe gastroenteritis worldwide and of diarrheal deaths in developing countries. Current vaccines (e.g., Rotarix, GlaxoSmithKline Biologicals; RotaTeq, Merck and Company) effectively reduce rotaviral gastroenteritis, emergency department visits, and hospitalizations. The tremendous burden of rotavirus-related diarrhea in children across the world continues to drive the remarkable pace of vaccine development. This review assesses the global epidemiological and economic burden of rotavirus diseases, summarizes the relevant principles of the development of rotavirus vaccines, and presents data on the efficacy and effectiveness of currently licensed vaccines in both developed and developing countries.
authors.affiliation: Department of Family Medicine, Da-Chien General Hospital, Miaoli, Taiwan.
authors.forename: Shou-Chien
authors.initials: SC
authors.lastname: Chen
authors.forename: Lia-Beng
authors.initials: LB
authors.lastname: Tan
authors.forename: Li-Min
authors.initials: LM
authors.lastname: Huang
authors.forename: Kow-Tong
authors.initials: KT
authors.lastname: Chen
mesh_terms: D005759:Gastroenteritis / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D012401:Rotavirus / Q000276:immunology; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D022243:Rotavirus Vaccines / Q000009:adverse effects / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
chemical_list: D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated